These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 31837884)
1. The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis. Tang H; Zhou X; Ye Y; Zhou Y; Wu C; Xu Y Pathol Res Pract; 2020 Jan; 216(1):152768. PubMed ID: 31837884 [TBL] [Abstract][Full Text] [Related]
2. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325 [TBL] [Abstract][Full Text] [Related]
3. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes. Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907 [TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis. Qin Y; Luan J; Zhou X; Li Y Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33704390 [TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. Sato F; Ono T; Kawahara A; Kawaguchi T; Tanaka H; Shimamatsu K; Kakuma T; Akiba J; Umeno H; Yano H J Clin Pathol; 2019 Aug; 72(8):542-549. PubMed ID: 31113825 [TBL] [Abstract][Full Text] [Related]
6. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma. Wuerdemann N; Gültekin SE; Pütz K; Wittekindt C; Huebbers CU; Sharma SJ; Eckel H; Schubotz AB; Gattenlöhner S; Büttner R; Speel EJ; Klussmann JP; Wagner S; Quaas A Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718057 [TBL] [Abstract][Full Text] [Related]
7. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression. Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J Front Immunol; 2021; 12():798424. PubMed ID: 35145511 [TBL] [Abstract][Full Text] [Related]
8. Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma. Zhu Y; Zhu X; Diao W; Liang Z; Gao Z; Chen X Clin Oral Investig; 2023 Apr; 27(4):1423-1433. PubMed ID: 36884083 [TBL] [Abstract][Full Text] [Related]
9. Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma. Brcic I; Gallob M; Schwantzer G; Zrnc T; Weiland T; Thurnher D; Wolf A; Brcic L Oral Oncol; 2020 Jul; 106():104719. PubMed ID: 32335324 [TBL] [Abstract][Full Text] [Related]
10. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis. Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X Front Immunol; 2021; 12():645170. PubMed ID: 33897693 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of PD-L1 Solomon B; Young RJ; Bressel M; Urban D; Hendry S; Thai A; Angel C; Haddad A; Kowanetz M; Fua T; Corry J; Fox S; Rischin D Cancer Immunol Res; 2018 Mar; 6(3):295-304. PubMed ID: 29378694 [TBL] [Abstract][Full Text] [Related]
12. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. Lenouvel D; González-Moles MÁ; Ruiz-Ávila I; Gonzalez-Ruiz L; Gonzalez-Ruiz I; Ramos-García P Oral Oncol; 2020 Jul; 106():104722. PubMed ID: 32330687 [TBL] [Abstract][Full Text] [Related]
13. Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma. Fukushima Y; Someya M; Nakata K; Hori M; Kitagawa M; Hasegawa T; Tsuchiya T; Gocho T; Ikeda H; Hirohashi Y; Torigoe T; Sugita S; Hasegawa T; Himi T; Sakata KI Radiother Oncol; 2018 Nov; 129(2):409-414. PubMed ID: 30249348 [TBL] [Abstract][Full Text] [Related]
14. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. He J; Chen XF; Xu MG; Zhao J Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357 [TBL] [Abstract][Full Text] [Related]
15. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697 [TBL] [Abstract][Full Text] [Related]
16. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma. Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146 [TBL] [Abstract][Full Text] [Related]
17. Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs. Ahmadvand S; Norouzi LA; Mohammadi Y; Safaei A; Khademi B; Motiee-Langroudi M; Ghaderi A BMC Immunol; 2024 Jan; 25(1):7. PubMed ID: 38229027 [TBL] [Abstract][Full Text] [Related]
18. Programmed Cell Death Ligand 1 Expression on Immune Cells and Survival in Patients With Nonmetastatic Head and Neck Cancer: A Systematic Review and Meta-analysis. Blažek T; Petráš M; Knybel L; Cvek J; Soumarová R JAMA Netw Open; 2023 Mar; 6(3):e236324. PubMed ID: 37000447 [TBL] [Abstract][Full Text] [Related]
19. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178 [TBL] [Abstract][Full Text] [Related]
20. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. Schneider S; Kadletz L; Wiebringhaus R; Kenner L; Selzer E; Füreder T; Rajky O; Berghoff AS; Preusser M; Heiduschka G Histopathology; 2018 Oct; 73(4):573-584. PubMed ID: 29742291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]